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ABSTRACT: Golgi mannosidase II (GMII) catalyzes the
sequential hydrolysis of two mannosyl residues from GlcNAc-
Man5GlcNAc2 to produce GlcNAcMan3GlcNAc2, the precursor for
all complex N-glycans, including the branched N-glycans associated
with cancer. Inhibitors of GMII are potential cancer therapeutics,
but their usefulness is limited by off-target effects, which produce
α-mannosidosis-like symptoms. Despite many structural and
mechanistic studies of GMII, we still lack a potent and selective
inhibitor of this enzyme. Here, we synthesized manno-epi-
cyclophellitol epoxide and aziridines and demonstrate their
covalent modification and time-dependent inhibition of GMII.
Application of fluorescent manno-epi-cyclophellitol aziridine
derivatives enabled activity-based protein profiling of α-mannosidases from both human cell lysate and mouse tissue extracts.
Synthesized probes also facilitated a fluorescence polarization-based screen for dGMII inhibitors. We identified seven previously
unknown inhibitors of GMII from a library of over 350 iminosugars and investigated their binding modalities through X-ray
crystallography. Our results reveal previously unobserved inhibitor binding modes and promising scaffolds for the generation of
selective GMII inhibitors.
■ INTRODUCTION
Golgi α-mannosidase (GMII, MAN2A1, mannosyl-oligosac-
charide 1,3/1,6-α-mannosidase) is a glycoside hydrolase from
CAZy family GH381 that catalyzes sequential hydrolysis of
both the terminal α-1,3- and 1,6-linked mannoses from the N-
glycan GlcNAcMan5GlcNAc2 (Figure 1A), which is a
committed step in the formation of complex N-glycans.2
Altered N-glycan branching has been directly linked to the
metastatic potential of cells,3,4 and consequently, inhibitors of
GMII are a potential target for anticancer therapeutics. The
potent GMII mannosidase inhibitor swainsonine (Figure 1B),
first identified in locoweed,5 has been investigated in this
capacity. Swainsonine treatment reduces metastasis and
improves outcome in breast, colon, and skin cancers.6−8
However, swainsonine also produces side effects resembling
the lysosomal storage disease α-mannosidosis9,10 resulting
from the off-target inhibition of lysosomal α-mannosidase
MAN2B1 (LAM).
As GMII is an important anticancer target, many studies
have sought to identify or design new and selective inhibitors.
One avenue that has been explored is the modification of
existing GMII inhibitors such as swainsonine and mannostatin
A (Figure 1B). Swainsonine derivatives containing C5-
substituents have been investigated, and although these
compounds maintain inhibitory potency against Drosophila
GMII (dGMII; 40% identity to human GMII), selectivity over
Drosophila lysosomal mannosidase (dLAM; 45% identity to
human LAM) is modest.11 Mannostatin A, a natural product
α-mannosidase inhibitor produced by Streptoverticillium
verticillus12 (Figure 1B), has also been derivatized in a similar
fashion;13 however the analogues had a reduced specificity for
human GMII over human LAM. Another class of inhibitor, the
hydroxylated pyrrolidines, has also been investigated in the
context of GMII inhibition. This class of mannosidase inhibitor
was first identified by Popowycz et al.,14 and functionalized
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hydroxylated pyrrolidines have subsequently been determined
to be more selective toward GMII.15−18 A different approach
to identify inhibitors was employed by Kuntz and co-
workers.19 Using a fluorogenic reporter substrate the authors
screened a focused library of potential glycosidase inhibitors
for action against dGMII. This study revealed several
compounds including glucoimidazole and mannoimidazole,
both with low micromolar inhibition constants for dGMII.
In the pursuit of new inhibitors of GMII we have applied the
considerable power of cyclophellitol-like activity-based probes
(ABPs).20 Herein we report the covalent inhibition of GMII
with manno-epi-cyclophellitol epoxide and aziridine. A
fluorescent derivative of the manno-epi-cyclophellitol aziridine
enabled activity-based protein profiling (ABPP) of GH38 α-
mannosidases in both cells overexpressing human GH38s and
mouse tissue extracts. This labeling could be reduced with
known inhibitors of GH38s. We next developed a high-
throughput fluorescence polarization ABPP screen for α-
mannosidase inhibitors. Screening of our in-house focused
library of over 350 iminosugars revealed seven previously
unidentified GMII inhibitors, some of which were found by X-
ray crystallography to bind in modes distinct from previously
observed inhibitors. Together this gives us fresh insight into
the design of GMII inhibitors and lead compounds for the
creation of second-generation GMII inhibitors while also
providing a high-throughput screening protocol for future
library assessment.
■ RESULTS AND DISCUSSION
Manno-epi-cyclophellitols Are Time-Dependent In-
hibitors of dGMII. GMII is a GH38 retaining α-D-
mannosidase that employs a two-step, double-displacement
mechanism in which a covalent-enzyme intermediate is flanked
by oxocarbenium-ion-like transition states.21 We reasoned that
as the GH38 mechanism processes through a covalent
intermediate, GMII would be an ideal target for the
cyclophellitol class of GH inhibitors, which have become a
powerful scaffold for the creation of activity-based glycosidase
probes.20 The cyclophellitol class of GH inhibitors covalently
modify retaining GHs, and activity-based probes bearing
cyclophellitol warheads have enabled high-throughput inhib-
itor and drug discovery,22 biomass enzyme profiling,23 and
detailed conformational and structural insight.24,25
Both the manno-epi-cyclophellitol epoxide (1) and aziridine
(2) were synthesized (see Figure 2 and the Supporting
Information for synthetic details) to ascertain whether these
inhibitors could target dGMII. When 1 and 2 were incubated
with recombinant dGMII, we observed that both displayed
time-dependent inhibition, which is typical for cyclophellitol-
type inhibitors (see Figure S1). To compare the reactivity of
these two compounds, second-order rate constants (kinact/KI)
were determined using 4-methylumbelliferyl α-D-mannopyr-
anoside (MU-α-Man) as a substrate. The kinact/KI value for 1
was determined to be 50 ± 5 min−1 M−1, while the observed
inhibition constant for aziridine 2 was over 100-fold higher
(5500 ± 100 min−1 M−1). This enhanced inhibition of 2 is
consistent with the trend previously observed for α-
glucosidases by epi-cyclophellitol epoxides and aziridines.26
We next obtained a crystal structure of dGMII that had been
soaked with aziridine 2. The reacted manno-epi-cyclophellitol
moiety is covalently linked to the nucleophile Asp204 in the X-
ray structure (Figure 3B). This structure clearly shows the
opening of the aziridine ring resulting from nucleophilic attack
at the pseudoanomeric carbon (Figure 3A). The resulting
enzyme-bound cyclitol structure displays a 1S5 skew boat
conformation, which is consistent with the proposed OS2/B2,5
→ B2,5
‡ → 1S5 reaction itinerary for GH38 α-mannosi-
dases.21,27 Comparison to the structure of 2-deoxy-2-fluoro-D-
mannose bound to the dGMII D341N acid/base mutant21
Figure 1. (A) Catalytic activity of Golgi α-mannosidase. (B)
Historical inhibitors of GMII.
Figure 2. Manno-epi-cyclophellitol inhibitors and probes used in this
work.
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(PDB ID: 1QX1) revealed excellent concordance with the
bound 2-fluorosugar-enzyme intermediate (Figure 3C).
The rapid time-dependent inactivation of dGMII by 2 and
the orientation of the amine toward the solvent suggested that
this inhibitor could serve as the scaffold for the design of
activity-based probes. Toward the goal of designing ABPs we
synthesized azido-n-octyl manno-epi-cyclophellitol (3, Figure
2) starting from D-ribose in 15 steps and used a copper(I)-
catalyzed azide−alkyne [2+3] cycloaddition to ligate this to
either Cy5-alkyne, biotin-alkyne, or 5′/6′-TAMRA-PEG4-
alkyne to yield ABPs 4, 5, and 6, respectively. Detailed
synthetic procedures are given in the Supporting Information.
Manno-epi-cyclophellitol Aziridine Probes React with
All Human GH38 α-Mannosidases. To determine whether
human mannosidases would react with the cyclophellitol
aziridine probes within complex mixtures, all five human GH38
α-mannosidases (epididymis-specific α-mannosidase (hEp-
man), hGMII, hLAM, hMan2A2, and hMan2C1) were
individually cloned and expressed in HEK293T cells, and
extracts thereof treated with 3 μM ABP 4 in buffers with pH
between 4 and 7.5 for 30 min at 37 °C. All five human GH38s
could be detected by in-gel fluorescence scanning of gels
containing SDS-PAGE-separated proteins with intensities
greater than that seen for a mock (no transfection) control.
In addition, each of the five cloned enzymes proved to react
with the probe in a pH-dependent manner. Lysates of cells
transfected with the Golgi-resident hGMII and hMan2A2 and
treated with 4 gave similar labeling patterns with bands at
approximately 140 kDa and maximal read-out at pH 5.5−6.0
(Figure 4A). Lysates of cells transfected with the lysosomal
hLAM gave multiple bands with highest intensities when
derived from samples treated at pH 4.0−5.5, with molecular
weights of ∼110, 65, 45, and 30 kDa. This band pattern reflects
the complex processing and maturation of hLAM in
lysosomes28 (Figure 4A) and moreover shows all the processed
forms to be reactive toward ABP 4.
Lysosomal hEpman has previously been purified from
HEK293 cells29 as a ∼110 kDa protein. Treatment of lysates
of cells transfected with lysosomal hEpman with ABP 4 gave
after SDS PAGE and gel slab fluorescence scanning the
expected band at ∼110 kDa, accompanied by an additional,
more intense band at ∼50 kDa, which we hypothesize
represents a previously unreported proteolytic product. Both
the ∼110 and 50 kDa band intensities were maximal from
samples treated at pH 4.0−5.5 (Figure 4A). Lysates of cells
transfected with the cytosolic hMan2C1 gave after ABP 4
treatment an expected band just above 100 kDa, matching
what has been previously reported for hMan2C1 over-
expression in HEK293 cells.30 Band intensity proved most
prominent at pH 5.5−7.5, which is more alkaline than those
witnessed for other GH38 enzymes expressed in HEK293T
cells (Figure 4A). While ABPP does not allow discriminating
the two Golgi GH38 α-mannosidases due to their similar pH
range and molecular weight, the other three enzymes are
readily identifiable by ABP labeling at different pH values
(Figure 4A).
Comparative ABPP Reveals Tissue-Dependent En-
zyme Activity Patterns.We next sought to establish whether
Figure 3. Covalent inhibition of dGMII with manno-epi-cyclophellitol aziridine. (A) Mechanism of covalent inhibition of α-mannosidase by
manno-epi-cyclophellitols. (B) Structure of 2 covalently linked to dGMII. The 2Fo−Fc map is contoured at 1.5 σ, (0.48 e−/Å3). (C) Overlay of 2
covalently bound to dGMII and 2-deoxy-2-fluoro-D-mannose bound to the D341N variant of dGMII (PDB: 1QX1). The bound (and reacted)
manno-epi-cyclophellitol aziridine is shown in green, while the bound 2-fluoromannose is shown in blue.
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the fluorescent ABP 4 could be used to profile GH38 α-
mannosidase activity across various tissues. We focused our
attention on mouse tissues as mice express homologues of all
five human GH38s, hereafter referred to as mGMII,
mMan2A2, mLAM, mEpman, and mMan2C1. Extracts from
mouse testes, epididymis, and brain were treated with 3 μM
ABP 4 for 30 min at 37 °C. Mouse testes and epididymis were
chosen, as both Man2A2 and Epman have been implicated in
spermatogenesis,31,32 while brain tissue was chosen, as
Man2C1 has previously been reported to be expressed in the
brain.33 Ensuing SDS PAGE separation of the protein content
and fluorescence imaging of the resultant wet gel slabs revealed
concentration-dependent labeling (Figure S2) and quite
distinct GH38 activity patterns (Figure 4B). Mouse mGMII
and mMan2A2 proved most prominently expressed in mouse
testis and less in mouse brain and epididymis. Mouse mLAM
Figure 4. (A) ABPP of lysate from HEK293T cells expressing human GH38 α-mannosidases. ABP 4 was used to show activity patterns for hGMII,
hMan2A2, hLAM, hEpman, and hMan2C1 expressing cells. (B) Differential activity of GH38 α-mannosidases in mouse tissue extracts labeled with
ABP 4. (C) Competitive ABPP of swainsonine or mannostatin A with ABP 4 in mouse testis homogenate. Arrows indicate bands that were
abolished by swainsonine preincubation. Arrows in B and C show positions of specific proteins with Man2A2, Epman, and Man2C1 abbreviated
A2, Ep, and C1, respectively.
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and mEpman in contrast are expressed by all tissues, while
detectable levels of mMan2C1 were only observed in mouse
brain (Figure 4B). In mouse epididymis extracts, the 65 and 45
kDa mLAM species seemed to have multiple forms that differ
in molecular weights, in contrast to the sharp bands obtained
from ABP 4-treated mouse brain extracts.
To allow identification of the GH38 mannosidases by means
of chemical proteomics, treatment of mouse testis extracts with
biotin-ABP 5 was performed. Samples incubated with ABP 5 at
either pH 4.5 or 6.0 were subjected to biotin affinity
enrichment and tryptic digestion (both on-bead digestion
and in-gel digestion), and finally LC-MS-based protein
identification. While silver staining of the gel containing the
affinity-enriched samples yielded few, if any, distinct bands
(Figure S3), the on-bead digest protocol identified mLAM and
mEpman from the sample treated with ABP 5 at pH 4.5 and all
five GH38 α-mannosidases in the sample treated at pH 6.0
(Table S3). No other glycosidases were detected in this
manner from these samples, and full peptide mass spec results
are available as Supporting Information.
Protein identity was also confirmed through a competitive
ABPP (cABPP) experiment. Mouse testis extracts were
preincubated with swainsonine or mannostatin A for 30 min
at pH 4.5 and then incubated with 3 μM ABP 4 for 10 min at
37 °C. The emergence of the 140, 50, 45, and 75 kDa bands
was reduced by swainsonine preincubation, and the 45 kDa
band was also competed away with 1 mM mannostatin A
(Figure 4C).
ABPP-Based Screening for GMII Inhibitors. The
successful detection of GH38 α-mannosidases and our ability
to block probe modification with competitive inhibitors
suggested that a high-throughput screen for inhibitors using
a fluorescence polarization (FluoPol) ABPP assay would work
as well. FluoPol screens offer several desirable qualities
including low requirements for both probe and enzyme and
the ability to screen complex enzyme mixtures.22,34 Further-
more, FluoPol ABPP enables specific targeting of competitive
inhibitors; inhibitors that bind after the probe will not result in
a decreased signal.
For FluoPol screening we used the TAMRA-derivatized
probe 6as opposed to the Cy5 derivative 4as TAMRA has
a longer fluorescence lifetime and thus may provide a better
signal-to-noise ratio.35 The TAMRA-derivatized ABP 6 also
displays time-dependent inhibition of dGMII, with an
inhibition constant of 2100 ± 300 min−1 M−1, approximately
2.6-fold less than 2 (see Figure S1). Initial tests toward such a
FluoPol ABPP assay were performed using 96-well plates with
each well containing 100 nM dGMII and 25 nM of probe and
the known inhibitors mannostatin A and swainsonine at
various concentrations. Protein concentration was set to be in
excess of the probe concentration to ensure maximum
fluorescence polarization signals. Although the pH optimum
for dGMII on chromogenic substrates has previously been
reported36 as 5.7, we observed an optimal ABP binding at pH
6.5. This alkaline shift is similar to what we observed for
human nonlysosomal glucosylceramidase (GBA2).22 The
inhibition curve for swainsonine shows reduced inhibition at
nanomolar concentrationsas this is a low nanomolar
inhibitor (Ki = 20 nM
19), this reflects the enzyme
concentration in the assaywhile the curve for mannostatin
A (Ki = 36 nM
37) showed reduced inhibition in the
micromolar range (see Figure 5A). Both inhibitors significantly
decreased polarization of TAMRA-emitted light in a
concentration-dependent manner, and a difference in polarized
light emission of approximately 250 mPol was achieved for the
completely inhibited enzyme. The resulting Z′-score for the
assay was >0.9, indicating that even with the low concentration
of ABP used, the assay is amenable for high-throughput
screening.38
We next screened our in-house library of 358 iminosugars
for dGMII inhibition. We used this continuously evolving
library previously to identify, in a FluoPol ABPP manner,
GBA2 inhibitors.22 The library includes, among others,
pyrrolidine and piperidine iminosugars featuring a variety of
configurations and N-alkylations. Screening was performed
with dGMII, which can be purified in reasonable quantities, as
necessary enzyme quantities were not known a priori.
However, the developed assay requires very little material
(0.58 nmol of dGMII and 0.15 nmol of 6 for two 384-well
plates); therefore it should enable future screening of α-
mannosidases that can only be obtained in small quantities. All
compounds in the iminosugar library were screened at a final
concentration of 5 μM, and the relative loss of fluorescence
polarization as a function of inhibitor was determined. A total
of seven compounds produced at least a 20% reduction in
activity of dGMII (robust Z-score > 3) and were selected for
further analysis (Figure 5). Two of these compounds are D-
lyxo-configured pyrrolidines (7 and 8), featuring different N-
alkyl substituents. The stereochemistry of the pseudoanomeric
carbon in these D-lyxo compounds is conserved and important
for binding, as compounds with the opposite pseudoanomeric
configuration that are also present in our library did not
significantly decrease dGMII activity.
Nearly one-third of the compounds in the library are (N-
alkylated) configurational deoxynojirimycin analogues. Only
one of these (9) reduced dGMII activity, which may not be
surprising given the poor inhibition of the enzyme by the
Figure 5. Screen validation, results, and identified inhibitors. (A) IC50
curves for mannostatin A and swainsonine determined with the
developed FluoPol assay. (B) FluoPol screening results. Red dashed
line indicates a Robust Z-score of −3. (C) Structures of the identified
inhibitors. Hydroxyls that interact with the active site zinc are shown
in blue.
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“parent” deoxymannojirimycin.39 Our FluoPol ABPP assay also
identified phenylpropyl-substituted glucoimidazole (10), the
only sugar-imidazole within the library, which is consistent
with the previous identification of both glucoimidazole and
mannoimidazole as dGMII inhibitors.15 The seven compounds
identified further include 2-hydroxymethyl-3-piperidinol (11)
and its 4,5-unsaturated analogue (12). The final inhibitor we
identified is 1-deoxy-L-allo-nojirimycin derivative (13), which
entails the first example, as far as we know, of an allose-
configured piperidine inhibiting dGMII.
To assess the inhibitory potency of the seven identified hits,
we determined IC50 values using the FluoPol assay and Ki
values using the fluorogenic MU-α-Man (Table 1, Figures S4
and S5). The ranking of the inhibitors is equivalent for both
IC50 and Ki, apart from 9 (Table 1). The most potent
inhibitors of dGMII proved to be the D-lyxo-configured
iminosugars, with Ki values of 8 and 10.8 μM for 7 and 8,
respectively. The hydroxylated pyrrolidine core of these
inhibitors has previously been reported,17 and a derivatized
version (Figure 1B) has been shown to be a nanomolar
inhibitor of hGMII.3 The tolerance of dGMII toward the bulky
adamantane-1-yl-methoxy ether warrants further studies to
investigate whether larger substituents would impart increased
inhibition and/or selectivity. Phenylpropyl-substituted glucoi-
midazole (10) also inhibited dGMII in the low micromolar
range (Ki: 12.5 μM). This corresponds very well with the
inhibition observed by Kuntz et al. for unsubstituted
glucoimidazole (Ki: 13 μM with dGMII).
15 The nearly
equivalent inhibition of the substituted glucoimidazole raises
the possibility that diversification of the substitution may
enable the future generation of selective inhibitors. The
remaining four identified inhibitors all had Ki values of <200
μM (Table 1) for dGMII despite little literature precedence for
their inhibition.
Ultimately, the therapeutic potential of discovered inhibitors
will rely on their inhibition of the human Golgi α-mannosidase
(hGMII). We therefore tested the inhibition of recombinant
hGMII with the identified inhibitors, under the same
conditions used for dGMII. All seven identified compounds
had inhibition constants in the micromolar range, though all
had higher inhibition constants for the human enzyme
compared to dGMII (Table 1). Nonetheless, five of the
seven identified inhibitors have Ki values of 100 μM or less for
hGMII.
We next performed cABPP with the inhibitors 8 and 10,
representing the two best classes of inhibitors discovered to
assess the inhibitor specificity. Mouse testis extracts were
preincubated with 8 or 10 for 30 min at pH 6.5 and then
incubated with 3 μM ABP 4 for 15 min at 37 °C. The 140, 50,
and 45 kDa bands (corresponding to mGMII/mMan2A2,
mEpman, and mLAM) were reduced by preincubation with 8
(Figure S9). Preincubation with 10 resulted in the loss of the
45 kDa band (mLAM) in the presence of 200 μM inhibitor
(Figure S9).
Crystallography of dGMII with Inhibitors. To further
understand the action of the α-mannosidase inhibitors, we
produced structures of dGMII, in complex with the inhibitors
by soaking dGMII crystals with solutions containing 7−13.
The electron density for the bound inhibitors allowed the
modeling of all inhibitors. Only the alkyl tails attached to 9, 10,
and 13 had poor density and were accordingly only partially
modeled. Unusual among GHs, GMII contains an active-site
zinc, which coordinates substrate 2- and 3-hydroxyls.21 All
seven inhibitors bind to the active site of dGMII and
coordinate to the active site zinc (Figures 6A, S6, and S7).
Both D-lyxo-configured iminosugars are bound in an NT4
conformation with 2- and 3-hydroxyls coordinating the active
site zinc. The alkyl groups of both 7 and 8 are projected
toward the “+” sugar binding sites. The observed NT4
conformation is consistent with the pyrrolidine inhibitor (Ki:
67 μM, PDB: 2F18) identified by Englebienne et al.40 This
inhibitor lacks the 5-hydroxymethyl substituent present in 7
and 8, which interacts with Asp472 and Tyr727 in the
structures presented here. Fiaux et al.15 also presented two
dGMII structures with pyrrolidone-based inhibitors resembling
7 and 8 (Ki: 22 and 1 μM, PDB: 3DDF and 3DDG). These
pyrrolidones, due to the planarity imposed by the lactam, are
present in a 3T2 conformation (numbering based on the D-lyxo
analogue) and can interact with Asp472 and Tyr727 through
the lactam carbonyl. The amide carbonyl of 7 and 8 is also
within hydrogen-bonding distance of an active site water, an
Table 1. Ki and IC50 Values for the Identified Inhibitors
inhibitor dGMII IC50 (μM)
a dGMII Ki (μM)
b hGMII Ki (μM)
b
7 6.1 ± 0.5 8.4 ± 0.4 20 ± 2
8 8.7 ± 0.9 10.8 ± 0.8 41 ± 3
9 50 ± 5 140 ± 40 270 ± 10
10 18 ± 2 12.5 ± 0.8 45 ± 6
11 18 ± 1 58 ± 3 100 ± 7
12 56 ± 6 180 ± 10 770 ± 70
13 22 ± 2 39 ± 2 51 ± 2
aDetermined using the FluoPol assay. bDetermined by initial rates of
MU-α-Man hydrolysis in the presence of inhibitor.
Figure 6. Configuration of bound dGMII inhibitors and structural
comparisons to known inhibitors. (A) Inhibitor density of the
identified inhibitors. The active site zinc is shown as a gray sphere,
and 2Fo−Fc maps are contoured at 1.5 σ, except for 5, which is
contoured at 1 σ. (B) Comparison of the binding of discovered
inhibitors to the binding of previously identified inhibitors. (i)
Overlay of 9 and deoxymannojirimycin (PDB: 1HXK). (ii) Overlay of
13 and noeuromycin (PDB: 2ALW). (iii) Overlay of 8 and a
derivatized pyrrolidinone (PDB: 3DDF). (iv) Overlay of 10 and
glucoimidazole (PDB: 3D4Z).
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interaction that is missing in PDB structures 2F18 and 3DDG.
An amide is also present in the derivatized pyrrolidine (Figure
1) identified by Cheng et al.;17 however it is positioned one
carbon away from the iminosugar ring, and therefore may not
be able to participate in this hydrogen bond. Incorporation of a
(4-fluorophenyl)acetamide, described by Cheng et al.,17 in
place of the alkyl substituent of 7 may indeed increase potency
of this inhibitor.
Investigation of the alkylated glucoimidazole inhibitor
revealed a binding mode similar to that previously seen for
glucoimidazole (Figure 6B). Both inhibitors are present in a
2H3/E3 conformation and coordinate the active site zinc with
the 2- and 3-hydroxyls. The electron density of the 7-
phenylpropyl could only be assigned to two of the alkyl
carbons (Figure 6A), suggesting conformational flexibility of
the alkyl group. Further investigation of derivatives at the 7-
position of glucoimidazole or mannoimidazolea better
inhibitorcould enable the creation of more potent and
selective inhibitors.
The two structures containing the hydroxylated piperidines
11 and 12 bind to dGMII in a very similar manner (Figure S7).
Unlike all other known inhibitors of dGMII that coordinate
zinc with two hydroxyls, 11 and 12 coordinate the active site
zinc with a single hydroxyl. This results in a five-coordinate
complex, as opposed to the six-coordinate zinc that is typically
observed. The hydroxyl that coordinates zinc is also within
hydrogen bond distance of Asp472 and the nucleophile
Asp204. The other hydroxyl is appropriately positioned to
form hydrogen bonds with Asp472 and Tyr727. The ring
nitrogen for both 11 and 12 also interacts closely (2.9 Å) with
the nucleophile Asp204. Although the polar interactions for 11
and 12 appear very similar, the piperidine ring conformations
are different (1C4 for 11 and
5HN for 12) due to the presence
of an unsaturated bond in 12.
The binding of 13 was also atypical for dGMII inhibitors
(Figures 6 and S6). Two pyranose iminosugars, namely,
noeuromycin41 (IC50: 20 μM, PDB: 2ALW) and deoxyman-
nojirimycin39 (DMJ, IC50: 400 μM, PDB: 1HXK), have
previously been shown to bind dGMII. When compared to
these two inhibitors, 13 appears to form interactions with
dGMII similar to noeuromycin (Figures 6B, S6), with 2- and 3-
OH coordinating with the active site zinc, the 4-OH hydrogen
bonding to Asp472 and Tyr727, the 6-OH hydrogen bonding
to Arg876, and the ring nitrogen positioned within 3 Å of the
nucleophile carbonyl (Asp204). However, the differing C4 and
C5 epimers of 13 necessitate a B1,4 conformation as opposed to
the 1S5 conformation of noeuromycin. The deoxynojirimycin
derivative 9 conversely appears to bind to dGMII in a manner
more akin to DMJ. In the structure of both 9 and DMJ, the
ring nitrogen is no longer in position to form a hydrogen bond
with the active site nucleophile, but instead hydrogen bonds to
an active site water. This loss of the interaction between the
ring nitrogen and the active site nucleophile is likely the cause
of the decreased relative inhibition of DMJ and 9 when
compared to 13 and noeuromycin. One final difference seen in
the structure of 9 binding to dGMII is the positioning of the 6-
OH. The structure with 9 shows the 6-OH hydrogen bonding
to the ω-nitrogen of Arg288, instead of the carbonyl of Arg876,
which is observed for all other pyranose iminosugars.
■ CONCLUSIONS
Manno-epi-cyclophellitols have proven to be powerful tools for
the study of GH38 α-mannosidases and the identification of
new inhibitors. The epoxide and aziridine analogues and
fluorescent derivatives are covalent time-dependent inhibitors.
X-ray crystallography has revealed the 1S5 conformation of
these cyclophellitols, which is consistent with theoretical
predictions for the glycosyl−enzyme intermediate. Fluorescent
derivatives have enabled the profiling of tissue-dependent
GH38 activity and a previously unseen proteolyzed form of
hEpman. Additionally, a FluoPol-ABPP screen with excellent
characteristics and low substrate and enzyme requirements was
developed using the fluorescently tagged manno-epi-cyclo-
phellitol aziridine. This screen revealed seven new inhibitors of
both dGMII and hGMII, including D-lyxo-configured pyrroli-
dines, deoxynojirimycins, hydroxylated piperidines, and an
alkylated glucoimidazole. X-ray crystallography of these
compounds bound to dGMII revealed both new binding
modes and potential sites for inhibitor diversification. This
work sets the stage for future development of selective GMII
inhibitors. Furthermore, the low material cost in terms of both
enzyme and substrate of the screen developed herein will
enable the screening of α-mannosidases, which may only be
expressed in small quantities. This in turn should enable the
screening for inhibitors of all human α-mannosidases.
■ EXPERIMENTAL SECTION
Methodology for protein expression, purification, kinetic analysis,
inhibitor-library screening, the conditions for crystal growth and
inhibitor soaking, the methods for data collection and structure
refinement, and the synthesis of manno-epi-cyclophellitol inhibitors
and probes are reported in the Supporting Information. The atomic
coordinates and structure factors have been deposited in the Protein
Data Bank. (PDB ID codes: 6RQZ, 6RRH, 6RRJ, 6RRN, 6RRW,
6RRU, 6RRX, 6RRY, and 6RS0).
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